Pages that link to "Q36765436"
Jump to navigation
Jump to search
The following pages link to Vascular disrupting agents in clinical development (Q36765436):
Displaying 50 items.
- Evolutionarily repurposed networks reveal the well-known antifungal drug thiabendazole to be a novel vascular disrupting agent (Q21145736) (← links)
- Development of a Novel Tumor-Targeted Vascular Disrupting Agent Activated by Membrane-Type Matrix Metalloproteinases (Q24617675) (← links)
- Tubulin-interactive natural products as anticancer agents (Q24650163) (← links)
- Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. (Q24651349) (← links)
- Perfusion CT imaging of colorectal cancer (Q27022129) (← links)
- Endothelial cell heterogeneity (Q28740296) (← links)
- Antivascular ultrasound therapy extends survival of mice with implanted melanomas (Q30475723) (← links)
- Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow. (Q30482804) (← links)
- Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation (Q30660860) (← links)
- Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a Tubulin Polymerization Inhibitor with Potent Antiproliferative and Tumor Vascular Disrupting Properties (Q31024172) (← links)
- Potential role of vascular targeted therapy to combat against tumor (Q33470615) (← links)
- Antivascular therapy for epithelial ovarian cancer (Q33583598) (← links)
- Design, synthesis, and biological evaluations of 2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoline analogs of combretastatin-A4. (Q33606508) (← links)
- A-ring dihalogenation increases the cellular activity of combretastatin-templated tetrazoles (Q33630470) (← links)
- Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform (Q33691051) (← links)
- Detection of tumor response to a vascular disrupting agent by hyperpolarized 13C magnetic resonance spectroscopy (Q33772430) (← links)
- An efficient synthetic strategy for obtaining 4-methoxy carbon isotope labeled combretastatin A-4 phosphate and other Z-combretastatins (Q33823154) (← links)
- Necrosis targeted combinational theragnostic approach using radioiodinated Sennidin A in rodent tumor models (Q33917524) (← links)
- Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. (Q34122854) (← links)
- A review on various targeted anticancer therapies (Q34164735) (← links)
- Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment (Q34208140) (← links)
- Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models (Q34430739) (← links)
- A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors (Q34546774) (← links)
- KML001 displays vascular disrupting properties and irinotecan combined antitumor activities in a murine tumor model (Q34551903) (← links)
- A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels (Q34746019) (← links)
- A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment (Q34765364) (← links)
- Nitrotyrosine Impairs Angiogenesis and Uncouples eNOS Activity of Pulmonary Artery Endothelial Cells Isolated From Developing Sheep Lungs (Q34912263) (← links)
- Nanoparticle Preconditioning for Enhanced Thermal Therapies in Cancer (Q34987068) (← links)
- Design and synthesis of 3,5-disubstituted boron-containing 1,2,4-oxadiazoles as potential combretastatin A-4 (CA-4) analogs (Q34987894) (← links)
- Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. (Q35205410) (← links)
- Cardiovascular toxicity profiles of vascular-disrupting agents (Q35584746) (← links)
- Current status of bevacizumab in advanced ovarian cancer (Q37048186) (← links)
- Delta-projection imaging on contrast-enhanced ultrasound to quantify tumor microvasculature and perfusion (Q37101638) (← links)
- Hybrid alpha-bromoacryloylamido chalcones. Design, synthesis and biological evaluation (Q37270597) (← links)
- Synthesis and biological evaluation of Combretastatin A-4 derivatives containing a 3'-O-substituted carbonic ether moiety as potential antitumor agents (Q37427582) (← links)
- Drug resistance associated with antiangiogenesis therapy (Q37518288) (← links)
- Synthesis and in vitro cytotoxic activity of novel chalcone-like agents (Q37540423) (← links)
- AVE8062: a new combretastatin derivative vascular disrupting agent. (Q37598267) (← links)
- Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy (Q37624281) (← links)
- The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities (Q37668618) (← links)
- Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer (Q37796083) (← links)
- Proceedings of the First Global Workshop on Breast Cancer: Pathways to the Evaluation and Clinical Development of Novel Agents for Breast Cancer (Q37819433) (← links)
- Optimizing radioimmunoconjugate delivery in the treatment of solid tumor (Q37973892) (← links)
- Beyond Bevacizumab: Antiangiogenic Agents (Q37980593) (← links)
- Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer (Q38151193) (← links)
- Modulation of in vivo tumor radiation response via gold nanoshell-mediated vascular-focused hyperthermia: characterizing an integrated antihypoxic and localized vascular disrupting targeting strategy (Q38262450) (← links)
- Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitor. (Q38322817) (← links)
- The ultra-performance liquid chromatography tandem mass spectrometry method for detection and quantification of C4NP in rat plasma and its application to pharmacokinetic studies (Q38452477) (← links)
- Discovery of a potent tubulin polymerization inhibitor: Synthesis and evaluation of water-soluble prodrugs of benzophenone analog (Q38481589) (← links)
- Identification of CKD-516: A Potent Tubulin Polymerization Inhibitor with Marked Antitumor Activity against Murine and Human Solid Tumors (Q38482781) (← links)